Hematology, Neurology Star In Swan Song For The Office Of New Drugs’ Division Structure
Executive Summary
Pink Sheet analysis of three years of novel US FDA approvals show the swiftest average time to approval in oncology, hematology, and antiviral divisions; neurology and hematology divisions contributed the most approvals.
You may also be interested in...
US FDA's Office Of New Drugs Reorganization Approved, But Not Happening Overnight
OND will grow to eight offices and 27 clinical divisions, which is slightly different than an early proposal.
Once More, With Statistics: FDA Defends Division Productivity Differences
Is it a problem that new drugs clear some review divisions faster than others? FDA analysis attributes differences to the proportion of applications qualifying for expedited review – a natural outgrowth of the priority placed on medical advances – not a management problem in need of a fix.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.